Approved TherapeuticAugust 5, 2026
Semaglutide
Ozempic
Type 2 diabetes · Chronic weight management
Tier 1Approved
SafetyKnown but Manageable Risks
- Sponsor
- Novo Nordisk
- Phase
- Approved
Loading Daily Peptide Guide…
The compounds people are searching for most. Interest is a signal for education, not a clinical endorsement.
Ozempic
Type 2 diabetes · Chronic weight management
Leuprorelin
Prostate cancer · Endometriosis
Lutathera
Gastroenteropancreatic neuroendocrine tumors · Theranostics
Zenagamtide
Obesity · Type 2 diabetes
ActRII pathway class
Muscle-wasting research · Neuromuscular disease research
HN peptide
Neuroprotection research · Longevity claims
Lys-Pro-Val
Inflammation claims · Skin and gut claims
Mounjaro
Type 2 diabetes · Chronic weight management
Gattex
Short bowel syndrome
LY3437943
Obesity · Type 2 diabetes
LY3841136
Obesity
GHS pathway class
Catabolic-disease research · Appetite research
Epithalon
Longevity claims · Sleep claims
Thymalfasin
Immune modulation · Infectious disease research
Victoza
Type 2 diabetes · Chronic weight management
Linzess
Irritable bowel syndrome with constipation · Chronic idiopathic constipation
Cagrilintide + semaglutide
Obesity · Type 2 diabetes
Experimental metabolic peptide
Obesity · Metabolic disease
APJ agonist programs
Metabolic research · Cardiovascular research
CJC-1295 DAC
Growth hormone claims · Body-composition claims
Tβ4
Wound-healing research · Recovery claims
Trulicity
Type 2 diabetes · Cardiovascular risk reduction
Trulance
Chronic idiopathic constipation · IBS-C
NN9833
Obesity · Type 2 diabetes
ZP8396
Obesity